サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1636006

てんかん治療薬市場：世代タイプ別、抗てんかん薬タイプ別、流通チャネル別、地域別、2025-2033年

Epilepsy Drugs Market by Generation Type, Anti-Epileptics Drugs Type, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 135 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
てんかん治療薬市場：世代タイプ別、抗てんかん薬タイプ別、流通チャネル別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

てんかん治療薬市場の世界市場規模は2024年に25億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに46億米ドルに達し、2025～2033年の成長率（CAGR）は6.87％になると予測しています。てんかんの世界の有病率の増加、薬剤開発と技術革新の著しい進展、てんかんとその治療選択肢に関する認知度の向上、ヘルスケア支出の増加と治療へのアクセスの改善が、市場成長を促進する主な要因の一部です。

てんかん治療薬とは、てんかんの治療に使用される薬剤のことであり、てんかんは、予測不能で、誘発性のない、再発性の発作を引き起こす中枢神経系（CNS）疾患です。てんかんは様々な精神的・身体的機能に影響を及ぼし、突然の行動変化、感覚、意識の喪失、深刻な精神的苦痛を引き起こします。てんかん治療薬には、錠剤、カプセル剤、液剤、シロップ剤などの第一世代、第二世代、第三世代の抗てんかん薬（AED）があり、経口投与、静脈内投与、筋肉内投与が行われています。てんかん治療薬は、部分発作、難治性発作、混合発作、強直間代発作、急性反復発作など、さまざまな発作の治療に広く用いられています。てんかん治療薬は安全で、忍容性が高く、生命を脅かす副作用を防ぎ、認知機能への悪影響を最小限に抑えることができます。

現在、神経疾患、出産関連傷害、感染症、薬物乱用、交通事故などの増加によりてんかんの有病率が上昇していることが、市場の成長を促す主な要因の一つとなっています。てんかん治療薬は、発作の除去、発作頻度の減少、長期治療に伴う副作用の回避のために広く使用されており、患者が通常の心理社会的・職業的活動を回復し、通常のライフスタイルを維持するのに役立っています。これに加えて、発作の原因となる脳腫瘍などの重大な病気を開発しやすい老年人口の増加が、もう一つの大きな成長促進要因として作用しています。さらに、手頃な価格で、副作用が少なく忍容性と有効性が改善された新薬や先進薬の開発に向けた広範な研究開発（R&D）活動が、現在、市場成長にプラスの影響を与えています。これとは別に、血清薬物濃度の変動を最小限に抑えながら投与間隔を長くすることができる最近の徐放性（ER）製剤の開発は、即放性（IR）製剤と比較して有効性と服薬アドヒアランスを向上させ、市場の成長を促進しています。さらに、この疾患について大衆を啓蒙し、研究を促進し、より良い治療選択肢を迅速化することで積極的な支援を提供するための様々な政府イニシアチブの実施が、市場の成長を促進しています。その他にも、新薬の承認の高まり、医療インフラ施設の急速な改善、神経疾患の利用可能な治療法に関する一般市民の意識の高まり、てんかんにまつわるスティグマの減少などが、市場の成長を後押しすると予測されています。

本レポートで扱う主な質問

  • 世界のてんかん治療薬市場はこれまでどのように推移してきたか？
  • 世界のてんかん治療薬市場における促進要因、抑制要因、機会は何か？
  • 各促進要因、抑制要因、機会が世界のてんかん治療薬市場に与える影響は？
  • 主要な地域市場とは？
  • 最も魅力的なてんかん治療薬市場はどの国か？
  • 世代タイプ別の市場内訳は？
  • てんかん治療薬市場で最も魅力的な世代タイプは？
  • 抗てんかん薬タイプ別の市場内訳は？
  • てんかん治療薬市場における最も魅力的な抗てんかん薬タイプは？
  • 流通チャネル別の市場内訳は？
  • てんかん治療薬市場において最も魅力的な流通チャネルは？
  • 市場の競合構造は？
  • 世界のてんかん治療薬市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のてんかん治療薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：世代タイプ別

  • 第一世代医薬品
    • 市場動向
    • 主要セグメント
      • フェニトイン
      • カルバマゼピン
      • オキシカルバゼピン
      • バルプロ酸
      • エトスクシミド
      • プリミドン
      • フェノバルビタール
    • 市場予測
  • 第二世代医薬品
    • 市場動向
    • 主要セグメント
      • レベチラセタム
      • ラモトリギン
      • トピラマート
      • プレガバリン
      • ルフィナミド
      • ゾニサミド
    • 市場予測
  • 第三世代医薬品
    • 市場動向
    • 主要セグメント
      • ラコサミド
      • ペランパネル
      • エスリカルバゼピン酢酸塩
      • エゾガビン/レチガビン
    • 市場予測

第7章 市場内訳：抗てんかん薬タイプ別

  • 狭域スペクトルAED
    • 市場動向
    • 市場予測
  • 広域スペクトルAED
    • 市場動向
    • 市場予測

第8章 市場内訳：流通チャネル別

  • 病院薬局
    • 市場動向
    • 市場予測
  • 薬局
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Alkem Laboratories Limited
    • Bausch Health Companies Inc.
    • Eisai Co. Ltd.
    • GSK plc
    • H. Lundbeck A/S
    • Jazz Pharmaceuticals plc
    • Novartis AG
    • Pfizer Inc.
    • Sunovion Pharmaceuticals Inc.（Sumitomo Dainippon Pharma Co. Ltd.）
    • UCB S.A.
図表

List of Figures

  • Figure 1: Global: Epilepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Epilepsy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Epilepsy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Epilepsy Drugs Market: Breakup by Generation Type (in %), 2024
  • Figure 5: Global: Epilepsy Drugs Market: Breakup by Anti-Epileptics Drugs Type (in %), 2024
  • Figure 6: Global: Epilepsy Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Epilepsy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Epilepsy Drugs (First Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Epilepsy Drugs (First Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Epilepsy Drugs (Second Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Epilepsy Drugs (Second Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Epilepsy Drugs (Third Generation Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Epilepsy Drugs (Third Generation Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Epilepsy Drugs (Narrow-Spectrum AEDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Epilepsy Drugs (Broad-Spectrum AEDs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Epilepsy Drugs (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Epilepsy Drugs (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Epilepsy Drugs (Pharmacy Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Epilepsy Drugs (Pharmacy Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Epilepsy Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Epilepsy Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: North America: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: North America: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: United States: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: United States: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Canada: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Canada: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Asia-Pacific: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Asia-Pacific: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: China: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: China: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Japan: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Japan: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: India: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: India: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: South Korea: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: South Korea: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Australia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Australia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Indonesia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Indonesia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Europe: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Europe: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Germany: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Germany: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: France: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: France: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: United Kingdom: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: United Kingdom: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Italy: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Italy: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Spain: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Spain: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Russia: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Russia: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Latin America: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Latin America: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Brazil: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Brazil: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Mexico: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Mexico: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Others: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Others: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Middle East and Africa: Epilepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Middle East and Africa: Epilepsy Drugs Market: Breakup by Country (in %), 2024
  • Figure 72: Middle East and Africa: Epilepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Epilepsy Drugs Industry: Drivers, Restraints, and Opportunities
  • Figure 74: Global: Epilepsy Drugs Industry: Value Chain Analysis
  • Figure 75: Global: Epilepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Epilepsy Drugs Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Epilepsy Drugs Market Forecast: Breakup by Generation Type (in Million USD), 2025-2033
  • Table 3: Global: Epilepsy Drugs Market Forecast: Breakup by Anti-Epileptics Drugs Type (in Million USD), 2025-2033
  • Table 4: Global: Epilepsy Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Epilepsy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Epilepsy Drugs Market: Competitive Structure
  • Table 7: Global: Epilepsy Drugs Market: Key Players
目次
Product Code: SR112025A6650

The global epilepsy drugs market size reached USD 2.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 6.87% during 2025-2033. The increasing prevalence of epilepsy worldwide, significant advancements in drug development and innovation, growing awareness about epilepsy and its treatment options, and rising healthcare expenditure and improving access to treatment are some of the key factors propelling the market growth.

Epilepsy drugs refer to medications used for treating epilepsy, a central nervous system (CNS) disorder that causes unpredictive, unprovoked, and recurrent episodes of seizures. Epilepsy affects various mental and physical functions causing sudden behavioral changes, sensations, loss of awareness, and severe emotional distress. Its medication includes first-, second-, and third-generation anti-epileptic drugs (AEDs), such as tablets, capsules, liquids, and syrups that are administered through oral, intravenous (IV), and intramuscular routes. Epilepsy drugs are widely used to treat various seizures, including partial onset, hard-to-treat, mixed, tonic-clonic, and acute repetitive seizures. Epilepsy drugs are safe, offer better tolerability, prevent life-threatening adverse effects, and minimize the negative impact on the cognitive functions.

At present, the rising prevalence of epilepsy due to increasing incidences of neurological disorders, birth-related injuries, infections, substance abuse, and road injuries is one of the primary factors driving the market growth. Epilepsy drugs are widely used to eliminate seizures, reduce their frequency, and evade the adverse effects associated with long-term treatments, thus helping patients in restoring their usual psychosocial and vocational activities and maintaining a normal lifestyle. In addition to this, the rising geriatric population that is prone to developing critical ailments, such as brain cancer, that can cause seizures, is acting as another major growth-inducing factor. Furthermore, extensive research and development (R&D) activities toward developing new and advanced drugs that are affordable and provide improved tolerability and efficacy with fewer side effects are currently positively influencing the market growth. Apart from this, the recent development of extended-release (ER) drug formulations that allow longer dosing intervals while minimizing the fluctuations in serum drug levels, thus improving efficacy and adherence as compared to immediate-release (IR) drugs, is facilitating the market growth. Moreover, the implementation of various government initiatives to educate the masses about the disorder, promote research, and provide active support by expediting better treatment options are propelling the market growth. Other factors, including the rising approval of novel drugs, rapid improvements in healthcare infrastructural facilities, increasing public awareness regarding the available treatments of neurological disorders, and the decreasing stigma associated with epilepsy, are anticipated to drive the market toward growth.

Key Market Segmentation:

Generation Type Insights

First Generation Drugs

Phenytoin

Carbamazepine

Oxcarbazepine

Valproate

Ethosuximide

Primidone

Phenobarbital

Second Generation Drugs

Levetiracetam

Lamotrigine

Topiramate

Pregabalin

Rufinamide

Zonisamide

Third Generation Drugs

Lacosamide

Perampanel

Eslicarbazepine Acetate

Ezogabine/Retigabine

The report has also provided a detailed breakup and analysis of the epilepsy drugs market based on the generation type. This includes first generation drugs (phenytoin, carbamazepine, oxcarbazepine, valproate, ethosuximide, primidone, and phenobarbital), second generation drugs (levetiracetam, lamotrigine, topiramate, pregabalin, rufinamide, and zonisamide), and third generation drugs (lacosamide, perampanel, eslicarbazepine acetate, and ezogabine/retigabine). According to the report, second generation drugs represented the largest segment.

Anti-Epileptics Drugs Type Insights

Narrow-Spectrum AEDs

Broad-Spectrum AEDs

Distribution Channel Insights

Hospital Pharmacy

Pharmacy Stores

Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for epilepsy drugs. Some of the factors driving the North America epilepsy drugs market growth include increasing burden of epilepsy, rising awareness campaigns, launching of new products, etc.
  • Competitive Landscape
  • The report has also provided a comprehensive analysis of the competitive landscape in the global epilepsy drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Alkem Laboratories Limited, Bausch Health Companies Inc., Eisai Co. Ltd., GSK plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Novartis AG, Pfizer Inc., Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.), UCB S.A., etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global epilepsy drugs market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global epilepsy drugs market?
  • What is the impact of each driver, restraint, and opportunity on the global epilepsy drugs market?
  • What are the key regional markets?
  • Which countries represent the most attractive epilepsy drugs market?
  • What is the breakup of the market based on the generation type?
  • Which is the most attractive generation type in the epilepsy drugs market?
  • What is the breakup of the market based on the anti-epileptics drugs type?
  • Which is the most attractive anti-epileptics drugs type in the epilepsy drugs market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the epilepsy drugs market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global epilepsy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Epilepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Generation Type

  • 6.1 First Generation Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Phenytoin
      • 6.1.2.2 Carbamazepine
      • 6.1.2.3 Oxcarbazepine
      • 6.1.2.4 Valproate
      • 6.1.2.5 Ethosuximide
      • 6.1.2.6 Primidone
      • 6.1.2.7 Phenobarbital
    • 6.1.3 Market Forecast
  • 6.2 Second Generation Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Levetiracetam
      • 6.2.2.2 Lamotrigine
      • 6.2.2.3 Topiramate
      • 6.2.2.4 Pregabalin
      • 6.2.2.5 Rufinamide
      • 6.2.2.6 Zonisamide
    • 6.2.3 Market Forecast
  • 6.3 Third Generation Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Key Segments
      • 6.3.2.1 Lacosamide
      • 6.3.2.2 Perampanel
      • 6.3.2.3 Eslicarbazepine Acetate
      • 6.3.2.4 Ezogabine/Retigabine
    • 6.3.3 Market Forecast

7 Market Breakup by Anti-Epileptics Drugs Type

  • 7.1 Narrow-Spectrum AEDs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Broad-Spectrum AEDs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Pharmacy Stores
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Alkem Laboratories Limited
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch Health Companies Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eisai Co. Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 GSK plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 H. Lundbeck A/S
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Jazz Pharmaceuticals plc
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Novartis AG
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Pfizer Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co. Ltd.)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 SWOT Analysis
    • 14.3.11 UCB S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report